Category: Markets
Published: 2026-06-22T16:33:24.000Z
bioAffinity Technologies announced promising preclinical results for its novel siRNA treatment, showing it selectively destroys squamous and basal skin cancer cells in vitro while leaving healthy cells unharmed. The company plans to use these findings to develop noninvasive, targeted topical therapies for common skin cancers, expanding on previous research into silencing specific cell surface receptors. Despite the positive laboratory data, the company's shares remained stable at $1.50 after the announcement, as human trials and regulatory submissions are still in the future.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.